BIOLASE, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0909117022
USD
0.00
0 (-100.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About BIOLASE, Inc. stock-summary
stock-summary
BIOLASE, Inc.
Pharmaceuticals & Biotechnology
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
Company Coordinates stock-summary
Company Details
4 CROMWELL , IRVINE CA : 92618-1816
stock-summary
Tel: 1 949 3611200
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.06%)

Foreign Institutions

Held by 6 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Jonathan Lord
Independent Chairman of the Board
Mr. Todd Norbe
President, Chief Executive Officer, Director
Dr. Michael DiTolla
Independent Director
Dr. Richard Lanman
Independent Director
Mr. Jess Roper
Independent Director
Mr. Garrett Sato
Independent Director
Dr. Elaine Wagner
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Sep 2024)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.64

stock-summary
Return on Equity

308.80%

stock-summary
Price to Book

-0.00